Muramyl dipeptide mitigates obesity-induced insulin resistance by targeting nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and interferon regulatory factor 4 (IRF4) [239]. This evidence concerns the gene IRF4 and Insulin resistance.